Fig. 1 · Structure
Documents & Downloads
Enapotamab vedotin
ADC
Enapotamab vedotin is an AXL-targeted antibody-drug conjugate (ADC) designed to specifically inhibit high AXL expressing non-small cell lung cancer (NSCLC). This compound demonstrates potential efficacy in overcoming resistance to EGFR inhibitors, including Osimertinib. Enapotamab vedotin is valuable for research focused on targeted cancer therapies and understanding AXL-related signaling pathways in oncogenesis.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 1912424-97-5 |
| Applications | ADC |
| Molecular Weight | 150.63 kDa |
| Synonyms | HuMax-AXL-ADC |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.